EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV–associated nasopharyngeal carcinoma

Xiang-Wei Kong, Guo-Long Bu, Hua Chen, Yu-Hua Huang, Zhiwei Liu, Yin-Feng Kang, Yan-Cheng Li, Xia Yu, Biao-Hua Wu, Zi-Qian Li, Xin-Chun Chen, Shang-Hang Xie und 15 weitere

Journal of Clinical Investigation · 17.02.2025 · 135 (4)

DOI: 10.1172/jci180216 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 26.11.2024. Verfasst von Xiang-Wei Kong und 26 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carc…. Hauptthemen laut MEDLINE: Antibodies, Viral, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Immunoglobulin G. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND EBV is associated with nasopharyngeal carcinoma (NPC), but the existence of a NPC protective antibody against EBV-associated antigens remains unclear. METHODS Patients with NPC and matched controls were identified from prospective cohorts comprising 75,481 participants in southern China. ELISA and conditional logistic regression were applied to assess the effects of gp42-IgG on NPC. The expression of HLA-II, the gp42 receptor, in nasopharyngeal atypical dysplasia and its effect on EBV infection of epithelial cells were evaluated. FINDINGS gp42-IgG titers were significantly lower in patients with NPC compared with controls across various follow-up years before NPC diagnosis ( P < 0.05). Individuals in the highest quartile for gp42-IgG titers had a 71% NPC risk reduction compared with those in the lowest quartile (ORs Q4vsQ1 = 0.29, 95% CIs = 0·15 to 0.55, P < 0.001). Each unit antibody titer increase was associated with a 34% lower risk of NPC (OR = 0.66, 95% CI = 0.54–0.81, P trend < 0.001). The protective effect of of gp42-IgG was observed in patients diagnosed 5 years or more, 1–5 years, and less than 1 year after blood collection ( P < 0.05). HLA-II expression was detected in 13 of 27 specimens of nasopharyngeal atypical dysplasia, and its overexpression substantially promoted epithelial cell–origin EBV infection. CONCLUSION Elevated EBV gp42-IgG titers can reduce NPC risk, indicating that gp42 is a potential EBV prophylactic vaccine target. TRIAL REGISTRATION NCT00941538, NCT02501980, ChiCTR2000028776, ChiCTR2100041628. FUNDING Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0501003), National Natural Science Foundation of China (82030046, 82073625, 81860601, 82373655), Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2019BT02Y198), and Central Financial Transfer Payment Projects of the Chinese Government, Cancer Research Grant of Zhongshan City.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralEpstein-Barr Virus InfectionsHerpesvirus 4, HumanImmunoglobulin GNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedChinaProspective Studies

Stichwörter der Autor:innen

AntigenEpidemiologyHead and neck cancerVaccinesVirology

Substanzen

Antibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYS…
  • Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Pathology, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
  • Central Financial Transfer Payment Projects of the Chinese Government, Cancer Research Grant of Zhongshan City

Zitieren

APA

Kong, X. W., Bu, G. L., Chen, H., Huang, Y. H., Liu, Z., Kang, Y. F., Li, Y. C., Yu, X., Wu, B. H., Li, Z. Q., Chen, X. C., Xie, S. H., Lin, D. F., Li, T., Yan, S. M., Han, R. K., Huang, N., Wang, Q. Y., Li, Y., …, & Zeng, M. S. (2025). A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV–associated nasopharyngeal carcinoma. Journal of Clinical Investigation, 135(4). https://doi.org/10.1172/jci180216

Vancouver

Kong XW, Bu GL, Chen H, Huang YH, Liu Z, Kang YF, et al. A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV–associated nasopharyngeal carcinoma. Journal of Clinical Investigation. 2025;135(4). doi:10.1172/jci180216

BibTeX
@article{Kong2025,
  author = {Kong, Xiang-Wei and Bu, Guo-Long and Chen, Hua and Huang, Yu-Hua and Liu, Zhiwei and Kang, Yin-Feng and Li, Yan-Cheng and Yu, Xia and Wu, Biao-Hua and Li, Zi-Qian and Chen, Xin-Chun and Xie, Shang-Hang and Lin, Dong-Feng and Li, Tong and Yan, Shu-Mei and Han, Run-Kun and Huang, Nan and Wang, Qian-Yu and Li, Yan and Zhang, Ao and Zhong, Qian and Huang, Xiao-Ming and Ye, Weimin and Ji, Ming-Fang and Cai, Yong-Lin and Cao, Su-Mei and Zeng, Mu-Sheng},
  title = {A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV–associated nasopharyngeal carcinoma},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {4},
  doi = {10.1172/jci180216}
}
Kostenlos starten →